WallStreetZenWallStreetZen

NASDAQ: EDIT
Editas Medicine Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EDIT

Based on 2 analysts offering 12 month price targets for Editas Medicine Inc

Min Forecast
$3.50+24.11%
Avg Forecast
$5.75+103.9%
Max Forecast
$8.00+183.69%

Should I buy or sell EDIT stock?

Based on 2 analysts offering ratings for Editas Medicine Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although EDIT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates EDIT as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their EDIT stock forecasts and price targets.

EDIT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-03-10
lockedlocked$00.00+00.00%2026-03-09

1 of 1

Forecast return on equity

Is EDIT forecast to generate an efficient return?

Company
-332.91%
Industry
64.47%
Market
171.75%
EDIT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EDIT forecast to generate an efficient return on assets?

Company
-48.7%
Industry
30.51%
EDIT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EDIT earnings per share forecast

What is EDIT's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$1.05
Avg 2 year Forecast
-$1.00
Avg 3 year Forecast
-$1.10

EDIT revenue forecast

What is EDIT's revenue in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
$26.6M-34.37%
Avg 2 year Forecast
$18.4M-54.64%
Avg 3 year Forecast
$11.0M-72.76%
EDIT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

EDIT revenue growth forecast

How is EDIT forecast to perform vs Biotechnology companies and vs the US market?

Company
-35.63%
Industry
36.66%
Market
14.06%
EDIT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
EDIT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

EDIT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EDIT$2.82$5.75+103.90%Strong Buy
NERV$6.39$10.50+64.32%Buy
TARA$5.17$25.25+388.39%Strong Buy
SGMT$8.60$24.25+181.98%Buy
NBP$2.35$9.00+282.98%Buy
View Top Biotech Stocks

Editas Medicine Stock Forecast FAQ

Is Editas Medicine Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: EDIT) stock is to Strong Buy EDIT stock.

Out of 2 analysts, 2 (100%) are recommending EDIT as a Strong Buy, 0 (0%) are recommending EDIT as a Buy, 0 (0%) are recommending EDIT as a Hold, 0 (0%) are recommending EDIT as a Sell, and 0 (0%) are recommending EDIT as a Strong Sell.

If you're new to stock investing, here's how to buy Editas Medicine stock.

What is EDIT's earnings growth forecast for 2026-2028?

(NASDAQ: EDIT) Editas Medicine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.3%.

Editas Medicine's earnings in 2026 is -$160,060,000.On average, 15 Wall Street analysts forecast EDIT's earnings for 2026 to be -$103,039,641, with the lowest EDIT earnings forecast at -$130,443,800, and the highest EDIT earnings forecast at -$41,106,240. On average, 14 Wall Street analysts forecast EDIT's earnings for 2027 to be -$97,891,573, with the lowest EDIT earnings forecast at -$123,729,781, and the highest EDIT earnings forecast at -$29,802,024.

In 2028, EDIT is forecast to generate -$107,463,455 in earnings, with the lowest earnings forecast at -$120,852,344 and the highest earnings forecast at -$95,572,007.

What is EDIT's revenue growth forecast for 2026-2028?

(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of -35.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Editas Medicine's revenue in 2026 is $40,520,000.On average, 15 Wall Street analysts forecast EDIT's revenue for 2026 to be $2,602,710,069, with the lowest EDIT revenue forecast at $383,658,236, and the highest EDIT revenue forecast at $10,173,794,296. On average, 14 Wall Street analysts forecast EDIT's revenue for 2027 to be $1,798,691,598, with the lowest EDIT revenue forecast at $0, and the highest EDIT revenue forecast at $4,696,387,872.

In 2028, EDIT is forecast to generate $1,080,115,381 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,596,795,963.

What is EDIT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: EDIT) forecast ROA is -48.7%, which is lower than the forecast US Biotechnology industry average of 30.51%.

What is EDIT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year EDIT price target, the average EDIT price target is $5.75, with the highest EDIT stock price forecast at $8.00 and the lowest EDIT stock price forecast at $3.50.

On average, Wall Street analysts predict that Editas Medicine's share price could reach $5.75 by Mar 10, 2027. The average Editas Medicine stock price prediction forecasts a potential upside of 103.9% from the current EDIT share price of $2.82.

What is EDIT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: EDIT) Editas Medicine's current Earnings Per Share (EPS) is -$1.80. On average, analysts forecast that EDIT's EPS will be -$1.05 for 2026, with the lowest EPS forecast at -$1.33, and the highest EPS forecast at -$0.42. On average, analysts forecast that EDIT's EPS will be -$1.00 for 2027, with the lowest EPS forecast at -$1.26, and the highest EPS forecast at -$0.30. In 2028, EDIT's EPS is forecast to hit -$1.10 (min: -$1.23, max: -$0.98).

What is EDIT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: EDIT) forecast ROE is -332.91%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.